MoonLake Immunotherapeutics (MLTX) Financial Statements (2025 and earlier)

Company Profile

Business Address DORFSTRASSE 29
ZUG, 6300
State of Incorp.
Fiscal Year End December 31
Industry (SIC) 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete Financial Analysis Financial Benchmarking

Balance Sheet (Statement of Financial Position) (USD)

9/30/2024
Q3
6/30/2024
Q2
3/31/2024
Q1
12/31/2023
Q4
9/30/2023
Q3
6/30/2023
Q2
3/31/2023
Q1
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments519,799,542547,054,751511,008,237495,978,708501,786,99763,050,157
Cash and cash equivalents342,791,142458,441,051451,169,337318,165,809501,786,99750,129,197
Short-term investments177,008,40088,613,70059,838,900177,812,899 12,920,960
Receivables1,676,8131,495,8761,056,862720,755619,767378,445
Prepaid expense15,405,5265,039,3432,102,2033,310,2813,960,3833,075,862
Total current assets:536,881,881553,589,970514,167,302500,009,744506,367,14766,504,464
Noncurrent Assets
Operating lease, right-of-use asset3,384,9533,698,5143,628,480169,422211,238246,256
Property, plant and equipment481,705509,816320,86539,52042,81046,099
Prepaid expense4,129,1516,318,8388,423,468   
Total noncurrent assets:7,995,80910,527,16812,372,813208,942254,048292,355
TOTAL ASSETS:544,877,690564,117,138526,540,115500,218,686506,621,19566,796,819
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities2,854,6612,323,9003,520,9665,171,7091,130,051813,778
Accounts payable176,434204,042264,522199,359225,97164,496
Accrued liabilities2,678,2272,119,8583,256,4444,972,350904,080749,282
Other undisclosed current liabilities9,427,3036,586,6206,444,7145,136,3086,004,5756,465,637
Total current liabilities:12,281,9648,910,5209,965,68010,308,0177,134,6267,279,415
Noncurrent Liabilities
Liabilities, other than long-term debt2,564,2292,820,2303,083,416268,483376,614405,255
Liability, pension and other postretirement and postemployment benefits541,949462,735583,426255,399323,597314,174
Operating lease, liability2,022,2802,357,4952,499,99013,08453,01791,081
Total noncurrent liabilities:2,564,2292,820,2303,083,416268,483376,614405,255
Total liabilities:14,846,19311,730,75013,049,09610,576,5007,511,2407,684,670
Equity
Equity, attributable to parent, including:520,663,737542,553,731495,675,683424,933,000489,797,00141,999,160
Additional paid in capital671,998,583670,185,376609,969,236531,271,953589,549,979131,308,849
Accumulated other comprehensive income3,256,9072,693,0962,357,6212,875,19835,124340,108
Accumulated deficit(154,598,140)(130,331,128)(116,657,472)(109,220,396)(99,794,347)(89,655,068)
Other undisclosed equity, attributable to parent6,3876,3876,2986,2456,2455,271
Equity, attributable to noncontrolling interest9,367,7609,832,65717,815,33664,709,1869,312,95417,112,989
Total equity:530,031,497552,386,388513,491,019489,642,186499,109,95559,112,149
TOTAL LIABILITIES AND EQUITY:544,877,690564,117,138526,540,115500,218,686506,621,19566,796,819

Income Statement (P&L) (USD)

9/30/2024
Q3
6/30/2024
Q2
3/31/2024
Q1
12/31/2023
Q4
9/30/2023
Q3
6/30/2023
Q2
3/31/2023
Q1
Operating expenses(30,578,201)(19,820,489)(15,028,892)(12,976,743)(13,185,890)(12,931,566)
Operating loss:(30,578,201)(19,820,489)(15,028,892)(12,976,743)(13,185,890)(12,931,566)
Nonoperating income5,898,1485,915,2207,337,3031,386,313842,652723,589
Other nonoperating income5,898,1485,915,2207,185,8101,386,313842,652723,589
Loss from continuing operations before equity method investments, income taxes:(24,680,053)(13,905,269)(7,691,589)(11,590,430)(12,343,238)(12,207,977)
Other undisclosed loss from continuing operations before income taxes   (151,493)   
Loss from continuing operations before income taxes:(24,680,053)(13,905,269)(7,843,082)(11,590,430)(12,343,238)(12,207,977)
Income tax expense(78,701)(70,252)(44,308)(28,923)(10,149)(11,010)
Net loss:(24,758,754)(13,975,521)(7,887,390)(11,619,353)(12,353,387)(12,218,987)
Net income attributable to noncontrolling interest491,742301,865450,3142,193,3042,214,1083,214,131
Net loss available to common stockholders, diluted:(24,267,012)(13,673,656)(7,437,076)(9,426,049)(10,139,279)(9,004,856)

Comprehensive Income (USD)

9/30/2024
Q3
6/30/2024
Q2
3/31/2024
Q1
12/31/2023
Q4
9/30/2023
Q3
6/30/2023
Q2
3/31/2023
Q1
Net loss:(24,758,754)(13,975,521)(7,887,390)(11,619,353)(12,353,387)(12,218,987)
Other comprehensive income (loss)575,618263,503(1,033,693)3,476,448(431,561)(17,672)
Comprehensive loss:(24,183,136)(13,712,018)(8,921,083)(8,142,905)(12,784,948)(12,236,659)
Comprehensive income, net of tax, attributable to noncontrolling interest479,935296,311505,2861,552,6462,296,7633,219,178
Comprehensive loss, net of tax, attributable to parent:(23,703,201)(13,415,707)(8,415,797)(6,590,259)(10,488,185)(9,017,481)

Statements Sources

The financial statements are based on the Company's filings with the U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: